Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 517-535

  Maayan, Lawrence ^a,b   Correll, Christoph U ^c,d,e  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; METFORMIN; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIPOLAR MANIA; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD; DISRUPTIVE BEHAVIOR; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPID METABOLISM; METABOLIC DISORDER; OBESITY; POLYPHARMACY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; CLINICAL TRIALS AS TOPIC; GLUCOSE METABOLISM DISORDERS; HUMANS; LIPID METABOLISM; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 84555189932     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0015     Document Type: Article

References (115)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999. (Pubitemid 29517559)
2. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD: Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 193:101-107, 2008.
3. Aman M, Arnold L, C McDougle, Vitiello B, Scahill L, Davies M: Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869-884, 2005. (Pubitemid 43042978)
4. Aman M, De Smedt G, Derivan A, Lyons B, Findling R, Risperidone D: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002. (Pubitemid 34832715)
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272, 2004.
6. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombin I, Moreno D: Olanzapine compared to que-tiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18:418-428, 2009.
7. Arman S, Sadramely MR, Nadi M, Koleini N: A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 29:1130-1134, 2008.
8. Armenteros J, Lewis J, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: A placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558-565, 2007. (Pubitemid 46642572)
9. Barness LA, Opitz JM, Gilbert-Barness E: Obesity: Genetic, molecular, and environmental aspects. Am J Med Genet A 143A:3016-3034, 2007. (Pubitemid 350274816)
10. Buitelaar J, van der Gaag R, Cohen-Kettenis P, Melman C: A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239-248, 2001. (Pubitemid 32428762)
11. Cali AM, Caprio S: Obesity in children and adolescents. J Clin Endocrinol Metab 93:S31-S36, 2008.
12. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, Paya B, Moreno D, de la Serna E, Arango C: Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach. J Child Adolesc Psy-chopharmacol 18:327-336, 2008.
13. Chang KD: The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry 69 (Suppl 4):4-8, 2008.
14. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:A42, 2006.
15. Correll CU: Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008.
16. Correll CU: Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health 12:93, 2009.
17. Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791, 2006. (Pubitemid 43932904)
18. Correll CU, Kratochvil CJ, March J: Developments in pediatric psy-chopharmacology: focus on stimulants, antidepressants and anti-psychotics. J Clin Psychiatry 72:655-670, 2011a.
19. Correll CU, Lencz T, Malhotra AK: Antipsychotic drugs and obesity. Trends Mol Med 17:97-107, 2011b.
20. Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P: QT interval duration and dispersion in children and adolescents treated with ziprasidone. J Clin Psychiatry 72:854-860, 2011c.
21. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773, 2009.
22. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177-206, 2006. (Pubitemid 41735243)
23. Correll CU, Sheridan EM, DelBello MP: Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: A comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116-141, 2010.
24. Cortese S, Angriman M, Maffeis C, Isnard P, Konofal E, Lecendreux M, Purper-OuakilD, VincenziB,Bernardina BD, Mouren MC: Attention-deficit/ hyperactivity disorder (ADHD) and obesity: A systematic review of the literature. Crit Rev Food Sci Nutr 48:524-537, 2008. (Pubitemid 351883143)
25. Davis PH, Dawson JD, Riley WA, Lauer RM: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 104:2815-2819, 2001. (Pubitemid 33126656)
26. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412-424, 2009.
27. De Hert M, Detraux J, van Winkel R, Correll CU: Antipsychotic medications: Metabolic, cardiovascular and cardiac risks. Nat Rev Endocrinol 2011 Epub ahead of print.
28. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU: Metabolic and endocrine adverse effects of second-generation an-tipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144-158, 2011.
29. DelBello M, Findling R, Earley W, Acevedo L, Stankowski J: Efficacy of quetiapine in children and adolescents with bipolar mania: A 3-week, double-blind, randomized, placebo-controlled trial. Presented at 46th Annual Meeting of the American College of Neuropsychopharmacology, Boca Raton, FL; 2007a.
30. DelBello M, Findling R, Wang P, Grundapaneni B, Versavel M: Efficacy and safety of ziprasidone in pediatric bipolar disorder. Presented at 63rd Annual Meeting of the Society of Biological Psychiatry, Washington, DC; 2008a.
31. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM: A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68:789-795, 2007b. (Pubitemid 46841865)
32. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM: A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11:483-493, 2009.
33. DelBello MP, Versavel M, Ice K, Keller D, Miceli J: Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psy-chopharmacol 18:491-499, 2008b.
34. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology 52:1338-1344, 1999. (Pubitemid 29190521)
35. Findling R, Cavus I, Pappadolulos E, Backinsky M, Schwartz J, Vanderburg D: A placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr Res 117:437, 2010a.
36. Findling R, Kline K, Mckenna K, Earley W, Stankowski J, Pathak S: Efficacy and safety of quetiapine in adolescents with schizophrenia: A 6-week, double-blind, randomized, placebo-controlled trial. Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL; 2008a.
37. Findling R, Nyilas M, Forbes R, McQuade R, Jin N, Iwamoto T: Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70:1441-1451, 2009.
38. Findling R, Robb A, Nyilas M, Forbes R, Jin N, Ivanova S: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432-1441, 2008b.
39. Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L: Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49:583-594, 2010b.
40. Findling RL, Kline K, Mckenna K, Earley WR, Stankowski, J, Pathak S: Efficacy and safety of quetiapine in adolescents with schizophrenia: A 6-week, double-blind, randomized, placebo-controlled trial. Presented at 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Chicago, IL; 2008c.
41. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509-516, 2000. (Pubitemid 30185547)
42. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holt-kamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114:273-280, 2007. (Pubitemid 46147166)
43. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599-1608, 2008.
44. Food and Drug Administration. Pediatric indications. Available from: www.fda.gov/./CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisoryCommittee/UCM164423.pdf, 2009, accessed January 2010.
45. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Par-ellada M, Moreno C, Arango C: Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621-645, 2011.
46. Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Arango C: Metabolic and hormonal side effectsinchildren and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166-1175, 2008. (Pubitemid 352031601)
47. Freeman-Fobbs P: Feeding our children to death: The tragedy of childhood obesity in America. J Natl Med Assoc 95:119, 2003. (Pubitemid 37099552)
48. Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB: Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 69:1953-1959, 2008.
49. Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V: Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord 11:687-700, 2009a.
50. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V: Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: Double-blind study. Br J Psychiatry 194:158-164, 2009b.
51. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF: A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611-621, 2009c.
52. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR: Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 11:229-238, 2001. (Pubitemid 32937635)
53. Hollander E, Wasserman S, Swanson E, Chaplin W, Schapiro M, Zagursky K: A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolescent Psychopharmacology 16:541-548, 2006. (Pubitemid 44737209)
54. Huang ES, Basu A, O'Grady M, Capretta JC: Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 32:2225-2229, 2009.
55. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC: A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18:317-326, 2008.
56. Jensen PS, Youngstrom EA, Steiner H, Findling RL, Meyer RE, Malone RP, Carlson GA, Coccaro EF, Aman MG, Blair J, Dougherty D, Ferris C, Flynn L, Green E, Hoagwood K, Hutch-inson J, Laughren T, Leve LD, Novins DK, Vitiello B: Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies. J Am Acad Child Adolesc Psychiatry 46:309-322, 2007.
57. Jerrell JM: Adverse events associated with psychotropic treatment in African American children and adolescents. J Natl Med Assoc 102:375-383, 2010.
58. Jerrell JM, McIntyre RS: Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 23:283-290, 2008. (Pubitemid 351982665)
59. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Grobbee DE: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371:1085-1097, 2008. (Pubitemid 351418005)
60. Kane JM, Correll CU: Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71:1115-1124, 2010.
61. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH: From the cover: Antipsychotic drug-induced weight gain mediated by hista-mine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 104:3456-3459, 2007. (Pubitemid 46364180)
62. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical an-tipsychotic therapy in children and adolescents. Am J Psychiatry 163:2072-2079, 2006. (Pubitemid 46114226)
63. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526, 2003.
64. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW: The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: A pooled analysis of 4 clinical trials. J Clin Psychiatry 70:247-258, 2009a.
65. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60-70, 2009b.
66. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL: Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090-1097, 1996. (Pubitemid 26422059)
67. Kumra S, Kranzler H, Gerbino-Rosen G, Kester H, De Thomas C, Kafantaris V, Correll C, Kane J: Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry 63:524-529, 2008a. (Pubitemid 351220784)
68. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34:60-71, 2008b. (Pubitemid 350262286)
69. Lewis D,Winner P, Saper J, Ness S, Polverejan E, Wang S, Kurland CL, Nye J, Yuen E, Eerdekens M, Ford L: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of to-piramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 123:924-934, 2009.
70. Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, Be-renson GS: Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA 290:2271-2276, 2003. (Pubitemid 37430559)
71. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223, 2005. (Pubitemid 41345943)
72. Luby J, Mrakotsky C, Stalets M, Belden A, Heffelfinger A, Williams M: Risperidone in preschool children with autistic spectrum disorders: An investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575-587, 2006. (Pubitemid 44737212)
73. Maayan L, Correll CU: Management of antipsychotic-related weight gain. Expert Rev Neurother 10:1175-1200, 2010.
74. Maayan L, Hoogendoorn C, Sweat V, Convit A: Disinhibited eating in obese adolescents is associated with orbitofrontal volume reductions and executive dysfunction. Obesity (Silver Spring) 19:1382-1387, 2011.
75. Maayan L, Vakhrusheva J, Correll CU: Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neu-ropsychopharmacology 35:1520-1530, 2010a.
76. Maayan L, Vakhrusheva J, Sheridan EM, Correll CU: Efficacy and tol-erability of risperidone across the age span: A meta-analytic comparison of placebo controlled trials. Presented at New Clinical Drug Evaluation Unit 50th Anniversary Meeting, Boca Raton, FL; 2010b.
77. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG: A placebo-controlled, fixed-dose study of ar-ipiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48: 1110-1119, 2009.
78. McDougle CJ, Stigler KA, Erickson CA, Posey DJ: Atypical antipsy-chotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69 (Suppl 4):15-20, 2008.
79. McIntyre RS, Jerrell JM: Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162:929-935, 2008.
80. Molnar D: The prevalence of the metabolic syndrome and type 2 diabetes mellitus in children and adolescents. Int J Obes Relat Metab Disord 28 (Suppl 3):S70-S74, 2004. (Pubitemid 39564321)
81. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J: Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. J Clin Psychopharmacol 29:26-32, 2009.
82. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW: Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 67: 17-24, 2010a.
83. Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW: Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 164:344-351, 2010b.
84. Nagaraj R, Singhi P, Malhi P: Risperidone in children with autism: Randomized, placebo-controlled, double-blind study. J Child Neurol 21:450-455, 2006. (Pubitemid 44069792)
85. Narula PK, Rehan HS, Unni KE, Gupta N. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial. Schizophr Res118:218-223, 2010.
86. Nathan BM, Moran A: Metabolic complications of obesity in childhood and adolescence: More than just diabetes. Curr Opin En-docrinol Diabetes Obes 15:21-29, 2008.
87. National Institute of Mental Health. Reducing weight gain and improving metabolic function in children being treated with antipsy-chotics. In: ClinicalTrials.gov Internet. Bethesda, MD: National Library of Medicine (US); 2000; cited December 1, 2009. Available from: http://clinicaltrials.gov/show/ NCT00806234 NLM Identifier: NCT00806234.
88. National Institutes of Health and Washington University School of Medicine. Metabolic Effects of Antipsychotics in Children (MEAC). In: ClinicalTrials.gov Internet. Bethesda, MD: National Library of Medicine (US); 2000; cited December 1, 2009. Available from: http://clinicaltrials.gov/show/ NCT00205699 NLM Identifier: NCT00205699.
89. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 19 (Suppl 1):1-93, 2005. (Pubitemid 40677047)
90. Nielsen J, Skadhede S, Correll CU: Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 35:1997-2004, 2010.
91. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 303:242-249, 2010.
92. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006. (Pubitemid 43848299)
93. Olfson M, Crystal S, Huang C, Gerhard T: Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49:13-23, 2010.
94. Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Time trends in schizophrenia mortality in Stockholm county, Sweden: Cohort study. BMJ 321:483-484, 2000. (Pubitemid 30623604)
95. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533-1540, 2009.
96. Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P: Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr 128:608-615, 1996. (Pubitemid 26137717)
97. Rosenbloom AL: Fetal and childhood nutrition in type 2 diabetes in children and adults. Pediatr Diabetes 1:34-39; discussion 39-40, 2000.
98. Safer DJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429-436, 2004. (Pubitemid 38944142)
99. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000. (Pubitemid 30127607)
100. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135, 2003. (Pubitemid 36418773)
101. Shaw P, Sporn A, Gogtay N, Overman G, Greenstein D, Gochman P, Tossell J, Lenane M, Rapoport J: Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721-730, 2006.
102. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F: Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634-e641, 2004. (Pubitemid 41647671)
103. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA: Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: Findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431, 2008.
104. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsycho-pharmacology 29:133-145, 2004. (Pubitemid 38068023)
105. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002. (Pubitemid 38338050)
106. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM: A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15-to 18-year-old adolescents. Int Clin Psychopharmacol 25:1-6, 2010.
107. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D: Weight gain in antipsychotic-naive patients: A review and meta-analysis. Psychol Med 40:187-200, 2010.
108. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann R, Biederman J: Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164:1547-1556, 2007. (Pubitemid 350069734)
109. Tramontina S, Zeni C, Ketzer C, Pheula G, Narvaez J, Rohde L: Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. J Clin Psychiatry 70:756-764, 2009.
110. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM: Youth with obesity and obesity-related type 2 diabetes mel-litus demonstrate abnormalities in carotid structure and function. Circulation 119:2913-2919, 2009.
111. Van Bellinghen M, De Troch C: Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5-13, 2001. (Pubitemid 32295178)
112. Vieweg WV, Kuhnley LJ, Kuhnley EJ, Anum EA, Sood B, Pandur-angi A, Silverman JJ: Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Prog Neuropsycho-pharmacol Biol Psychiatry 29:511-515, 2005. (Pubitemid 40603824)
113. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, Allen K, Lopes M, Savoye M, Morrison J, Sherwin RS, Caprio S: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362-2374, 2004. (Pubitemid 38702847)
114. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Bieder-man J: Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psycho-pharmacol 19:539-545, 2009.
115. Yau PL, Javier DC, Ryan CM, Tsui WH, Ardekani BA, Ten S, Convit A: Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 53:2298-2306, 2010.